To hold pharmaceutical companies accountable for illegal marketing and distribution of opioid products and for their role in creating and exacerbating the opioid epidemic in the United States.
USA115th CongressHR-5782| House
| Updated: 5/31/2018
Tulsi Gabbard
Democratic Representative
Hawaii
Cosponsors (5)
Ways and Means Committee, Health Subcommittee, Judiciary Committee, Energy and Commerce Committee, Education and Workforce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Opioid Crisis Accountability Act of 2018 This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit a drug manufacturer from engaging in illegal marketing and distribution practices, including falsely advertising, promoting, or marketing that an opioid has no addiction-forming or addiction-sustaining qualities or risks, supplying states or communities with a quantity of opioids that is not medically necessary, or failing to report any order or pattern of orders that would cause a reasonable person to believe the opioids were not being dispensed in a medically reasonable manner.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and the Workforce, Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Health
Business ethicsBusiness expensesBusiness recordsChild healthCivil actions and liabilityCorporate finance and managementDepartment of Health and Human ServicesDepartment of JusticeDepartment of LaborDrug, alcohol, tobacco useDrug safety, medical device, and laboratory regulationDrug trafficking and controlled substancesEducation programs fundingElementary and secondary educationEmployment taxesExecutive agency funding and structureGovernment information and archivesGovernment studies and investigationsGovernment trust fundsHealth programs administration and fundingHealth promotion and preventive careIncome tax creditsMarketing and advertisingMedical researchPreschool educationPrescription drugsResearch and developmentSecuritiesSmall businessWages and earnings
To hold pharmaceutical companies accountable for illegal marketing and distribution of opioid products and for their role in creating and exacerbating the opioid epidemic in the United States.
USA115th CongressHR-5782| House
| Updated: 5/31/2018
Opioid Crisis Accountability Act of 2018 This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit a drug manufacturer from engaging in illegal marketing and distribution practices, including falsely advertising, promoting, or marketing that an opioid has no addiction-forming or addiction-sustaining qualities or risks, supplying states or communities with a quantity of opioids that is not medically necessary, or failing to report any order or pattern of orders that would cause a reasonable person to believe the opioids were not being dispensed in a medically reasonable manner.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and the Workforce, Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Tulsi Gabbard
Democratic Representative
Hawaii
Cosponsors (5)
Ways and Means Committee, Health Subcommittee, Judiciary Committee, Energy and Commerce Committee, Education and Workforce Committee
Health
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Business ethicsBusiness expensesBusiness recordsChild healthCivil actions and liabilityCorporate finance and managementDepartment of Health and Human ServicesDepartment of JusticeDepartment of LaborDrug, alcohol, tobacco useDrug safety, medical device, and laboratory regulationDrug trafficking and controlled substancesEducation programs fundingElementary and secondary educationEmployment taxesExecutive agency funding and structureGovernment information and archivesGovernment studies and investigationsGovernment trust fundsHealth programs administration and fundingHealth promotion and preventive careIncome tax creditsMarketing and advertisingMedical researchPreschool educationPrescription drugsResearch and developmentSecuritiesSmall businessWages and earnings